tanshinone has been researched along with Shock, Septic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Z; Fang, Z; Hong, Z; Hou, X; Liu, H; Liu, T; Luo, W; Mu, W; Ren, L; Shi, W; Wei, Z; Wen, J; Xiao, X; Xu, G; Yang, Y; Zhan, X; Zhao, J; Zou, W | 1 |
| Chen, H; Deng, W; Hu, W; Hua, L; Liang, S; Ou, Y; Sun, P; Yang, Z; Yue, H; Zhang, C | 1 |
| Chen, X; Dai, Y; Fu, L; Lv, Y; Qi, B; Qian, Y; Quan, M | 1 |
3 other study(ies) available for tanshinone and Shock, Septic
| Article | Year |
|---|---|
Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Shock, Septic | 2023 |
Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation.
Topics: Abietanes; AMP-Activated Protein Kinases; Animals; Autophagy; Disease Models, Animal; Female; Furans; Gout; Humans; Inflammasomes; Inflammation; Male; Mice; Mitochondria; NLR Family, Pyrin Domain-Containing 3 Protein; Phenanthrenes; Quinones; Rats; Reactive Oxygen Species; Shock, Septic; Uric Acid | 2021 |
Tanshinone IIA protects against lipopolysaccharide-induced lung injury through targeting Sirt1.
Topics: Abietanes; Acute Lung Injury; Animals; Carbazoles; Cytokines; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Shock, Septic; Signal Transduction; Sirtuin 1; Transcription Factor RelA | 2019 |